HRUNKA, Matěj, Lubomír JANDA, Michaela ŠŤASTNÁ, Tereza PINKASOVÁ, Jakub PECL, Lumír KUNOVSKÝ, Petr DÍTĚ and Petr JABANDŽIEV. Celiac Disease: Promising Biomarkers for Follow-Up. Journal of gastrointestinal and liver diseases : JGLD. CLUJ-NAPOCA: MEDICAL UNIV PRESS, 2023, vol. 32, No 4, p. 536-544. ISSN 1841-8724. Available from: https://dx.doi.org/10.15403/JGLD-4926.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Celiac Disease: Promising Biomarkers for Follow-Up
Authors HRUNKA, Matěj (203 Czech Republic, belonging to the institution), Lubomír JANDA (203 Czech Republic), Michaela ŠŤASTNÁ (203 Czech Republic), Tereza PINKASOVÁ (203 Czech Republic, belonging to the institution), Jakub PECL (203 Czech Republic, belonging to the institution), Lumír KUNOVSKÝ (203 Czech Republic, belonging to the institution), Petr DÍTĚ (203 Czech Republic, belonging to the institution) and Petr JABANDŽIEV (203 Czech Republic, belonging to the institution).
Edition Journal of gastrointestinal and liver diseases : JGLD, CLUJ-NAPOCA, MEDICAL UNIV PRESS, 2023, 1841-8724.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30219 Gastroenterology and hepatology
Country of publisher Romania
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.100 in 2022
RIV identification code RIV/00216224:14110/23:00132727
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.15403/JGLD-4926
UT WoS 001158173500017
Keywords in English celiac disease; novel biomarkers; microRNAs; gluten immunogenic peptide; citrulline; IgA deficiency
Tags 14110213, 14110223, 14110317, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 8/3/2024 07:31.
Abstract
Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients’ adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.
PrintDisplayed: 3/5/2024 14:45